Navigation Links
Bioengineered proteins: Trial confirms new way to tackle cancer
Date:3/25/2009

Re-engineering a protein that helps prevent tumours spreading and growing has created a potentially powerful therapy for people with many different types of cancer. In a study published in the first issue of EMBO Molecular Medicine, Canadian researchers modified the tumour inhibiting protein, von Hippel-Lindau (VHL), and demonstrated that it could suppress tumour growth in mice.

When solid tumours grow they often have relatively poor and disorganised blood supplies. As a result, various regions including the centre of the tumour have low levels of oxygen and are said to be hypoxic. Cells in these hypoxic areas produce hypoxia-inducible factor (HIF) that helps them carry on growing. Consequently HIF is associated with aggressiveness in some of the most common types of cancer, including prostate, breast, colon and lung cancer. Under normal conditions VHL degrades HIF, but VHL is deactivated when oxygen levels are low. So, in hypoxic regions of a tumour, just where VHL is needed to inhibit cancer, it is ineffective.

The researchers, therefore, created a new version of VHL that does not stop working when oxygen is scarce. Introducing this newly engineered version of VHL into mice that had kidney tumours dramatically reduced levels of HIF, caused tumours to regress and limited the formation of new blood vessels within the tumours.

"We have genetically removed the Achilles' heel of VHL to permit unrestricted destruction of HIF," says lead researcher Professor Michael Ohh, who works in the Faculty of Medicine at the University of Toronto. "The level of HIF is usually very high under conditions of low oxygen, but when we put in our bioengineered VHL its levels go right down to a level that would be comparable to that in normal oxygen levels."

Their findings could have implications for any type of cancer in which HIF plays a role. "We used kidney cancer as a model because it is one of the most resistant tumours to conventional radiation and chemotherapy, but our findings provide a novel concept that could potentially serve as a foundation for smarter anti-cancer strategy for a wide variety of cancers," says Ohh.


'/>"/>

Contact: Jennifer Beal
wbnewseurope@wiley.com
44-012-437-70633
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Reconstructing mandibular defects with bioengineered tooth and bone
2. Pressured proteins: A little pressure in proteomics squeezes 4-hour step into a minute
3. New Heart Pump Shows Promise in Trial
4. Trial to Test Gene Therapy for Angina in Women
5. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
6. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
7. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
8. MDS Pharma Services Wins Award for Management of Global Malaria Trial
9. New Ovarian Cancer Drug Trial Under Way
10. Study Questions Dead-End Cancer Clinical Trials
11. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... California (PRWEB) , ... January 17, 2017 , ... ... have a point of difference. Eden Activewear is a stand-out company for several ... are exclusively online and only manufacture on demand, this is called 'Agile' manufacturing ...
(Date:1/17/2017)... ... January 17, 2017 , ... Healthful Balance announces ... company, owned and operated by Ed Stroup, was created to offer the highest ... highest level of customer service. Healthful Balance products can be purchased online through ...
(Date:1/17/2017)... Grove Village, IL (PRWEB) , ... January 17, ... ... for musicians and music enthusiasts at the National Association of Music Merchants (NAMM) ... January 19 – 22, 2017. , Etymotic’s ER•4® has long been the gold ...
(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s ... honor of Diamond Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD ... elite group of providers. , Produced by Zeltiq, CoolSculpting is approved by the ...
(Date:1/17/2017)... ... January 17, 2017 , ... Surgeons from ... primary eye care practitioners on the latest breakthroughs in the prevention, diagnosis and ... Education Symposium, according to eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive Officer ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... Md. , Jan. 18, 2017  Kratom ... the coffee family, are often used to prepare ... consumed by several million Americans annually to increase ... a natural remedy for minor aches and pains. ... effects is intended to assist FDA and DEA ...
(Date:1/18/2017)... , Jan. 18, 2017 Safe Rx LLC ... pharmacies based in Loveland, Colorado , ... (LPVs) in selected Good Day locations.     ... cost-effective alternative for secure storage," said Milton Cohen ... than the price of a cup of coffee, you ...
(Date:1/18/2017)... DIEGO , Jan. 18, 2017 ... solutions for cell and advanced therapies , has ... French biopharmaceutical company developing "tumor starvation" treatments for ... medical needs. Under the agreement, Invetech will develop ... based on Erytech,s proprietary ERYCAPS technology platform, which ...
Breaking Medicine Technology: